A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Inclusion Criteria: * Histologically confirmed squamous advanced NSCLC (Stage IV). * Participants must have progressed on one prior line of platinum-based chemotherapy in the advanced or metastatic setting. * Measurable disease as measured by response evaluation criteria in solid tumors (RECIST) criteria v 1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. * Able to swallow the study drugs whole. * Adequate organ function. * Women of childbearing potential must have a negative serum or urine pregnancy test performed ≤ 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and during the 3 months following completion of study treatment. Exclusion Criteria: * Participants who have received \> 1 prior line of chemotherapy in the advanced or metastatic setting. (Immunotherapy will not be considered a line of chemotherapy.) * Prior treatment with a PI3K/mTOR inhibitor, epidermal growth factor receptor (EGFR) inhibitor, and/or necitumumab. * History of brain metastases unless irradiated ≥ 2 weeks prior to first study treatment and stable without requirement of corticosteroids. * Have serious pre-existing medical conditions. * Have insulin-dependent diabetes mellitus. Participants with a type 2 diabetes mellitus are eligible if adequate control of blood glucose level is obtained by oral anti-diabetics. * Women who are pregnant or breast-feeding. * Clinically significant electrolyte imbalance ≥ Grade 2. * Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin and oral Xa inhibitors are allowed. * Have initiated treatment with bisphosphonates or approved receptor activator of nuclear factor kappa-B ligand (RANK-L) targeted agents (e.g. denosumab) ≤ 28 days prior to Day 1 of Cycle 1. * Concurrent serious infection requiring parenteral antibiotic therapy. * Have a second primary malignancy that in the judgment of the investigator and Medical Monitor may affect the interpretation of results. * Have an active, known fungal, bacterial, and/or known viral infection. * History of arterial or venous embolism within 3 months prior to study enrollment. If the embolism occurred \>3 and \<6 months, the participant is eligible provided appropriate treatment according to institutional standard of care is ensured.